Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
  • Management of Immunotherapy-Related Toxicities
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Team-Based Management of Immunotherapy-Related Toxicities
Continuing education on the importance of early recognition and management of immunotherapy-related toxicities and involvement of the multidisciplinary team will be crucial to ensure optimal outcomes for patients with cancer.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Management of Immunotherapy-Associated Oral Toxicities
Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Pharmacy Updates: Management of Immunotherapy-Associated Oral Toxicities
Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date June 10, 2024